John Petrie, MD, PhD

John Petrie, MD, PhD

Professor of Diabetic Medicine
University of Glasgow
Honorary Consultant Physician and Diabetologist
Glasgow Royal Infirmary and Stobhill Hospital
Glasgow, Scotland

Related Videos

What is your assessment of the secondary end points -- especially renal markers such as albuminuria -- reported in LEADER that may be drivers of atheroinflammatory CV disease? Video

What is your assessment of the secondary end points -- especially renal markers such as albuminuria -- reported in LEADER that may be drivers of atheroinflammatory CV disease?

What is your assessment of the results of the secondary end points — especially renal markers such as albuminuria — reported in LEADER that may be drivers of atheroinflammatory CV disease? What about the absence of a cancer signal?

What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated? Video

What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?

What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?

Based on LEADER, what does the typical T2D patient look like who could possibly benefit from CV risk reduction associated with GLP-1 RA therapy? What doses of liraglutide appear to be optimal? Video

Based on LEADER, what does the typical T2D patient look like who could possibly benefit from CV risk reduction associated with GLP-1 RA therapy? What doses of liraglutide appear to be optimal?

Based on LEADER, what does the typical patient with T2D look like who could possibly benefit from CV risk reduction associated with GLP-1 RA therapy? What doses of liraglutide would appear to be optimal?

By what mechanisms do you think the GLP-1 RA liraglutide might have affected cardiovascular events, based on the finding of the LEADER trial? Video

By what mechanisms do you think the GLP-1 RA liraglutide might have affected cardiovascular events, based on the finding of the LEADER trial?

By what mechanisms do you think the GLP-1 RA liraglutide might have affected cardiovascular events, based on the finding of the LEADER trial?

In your mind, what are the most impressive results reported for both primary and secondary end points in the LEADER trial? Video

In your mind, what are the most impressive results reported for both primary and secondary end points in the LEADER trial?

In your mind, what are the most impressive results reported for both primary and secondary end points in the LEADER trial?